Scottish HTA Body OKs Novartis Aimovig For Migraine And Eisais Lenvima For Cancer

Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer

08:12 EDT 10 Apr 2019 | Elsevier Business Intelligence

Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a me...

More From BioPortfolio on "Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer"